Array BioPharma announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as a monotherapy. The combination reduced the risk of death compared to treatment with vemurafenib alone. The observed efficacy of vemurafenib in the control arm is also consistent with historical data, providing an additional benchmark for validating the patient population and results observed in COLUMBUS. Further, the two-year OS with combination therapy was 58%. These results will be part of an oral presentation at the American Society of Clinical Oncology annual meeting in Chicago, Illinois and have been selected for the “Best of ASCO” program
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.